Dr. Greenbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1660 S Columbian Way
Seattle, WA 98108Phone+1 206-762-1010- Is this information wrong?
Summary
- I am a board-certified medical oncologist who works in drug development.
Education & Training
University of Washington School of MedicineFellowship, Oncology/Bmt, 2015 - 2019
University of California (San Diego) Medical CenterResidency, Internal Medicine, 2013 - 2015
Washington University in St. Louis School of MedicineClass of 2012, MD/PhD
Washington University in St. LouisBS, Computer Science, Magnum Cum Laude, 2001 - 2005
Certifications & Licensure
CA State Medical License 2014 - Present
WA State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Start of enrollment: 2017 Dec 05
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Mar 23
- Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Start of enrollment: 2018 Jul 09
Publications & Presentations
PubMed
- 3 citationsDiffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8T-cells despite immune checkpoint signaling.Adam M Greenbaum, Jonathan R Fromm, Ajay K Gopal, A McGarry Houghton> ;Blood Research. 2022 Jun 30
- Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma.Adam Greenbaum, Damian J. Green, Leona Holmberg, Ted Gooley, Brian G. Till, Lihua E. Budde, Heather A. Rasmussen, Oliver W. Press, Ajay K. Gopal> ;Blood Research. 2018 Sep 1
- 2 citationsCutaneous phaeohyphomycosis in a hematopoietic stem cell transplant patient caused by Alternaria rosae: First case reportAmy W. Liu, Allen C. Bateman, Adam Greenbaum, Kanishka W. Garvin, Jill E. Clarridge, Jonathan A. Grim> ;Transplant Infectious Disease. 2017 May 4
- Join now to see all
Abstracts/Posters
- High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic TrialsAdam Greenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin LymphomasAdam Greenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Links to the ACC.22 Late-Breaking Clinical TrialsApril 13th, 2022
Grant Support
- Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)National Institutes of Health2009–2012
- Research Training Award for FellowsAmerican Society of HematologyPresent
Research History
- Postdoctoral fellowMechanisms of Immune Failure in Non-Hodgkin Lymphoma2016 - Present
- Ph.D. studentHematopoietic stem cells (HSCs) reside in the bone marrow supported by the surrounding stromal compartment. Using a novel conditional knockout of CXCL12 to delete the gene from four stromal compartments, I demonstrated that HSCs are supported by mesenchymal stem cells.2007 - 2011
Professional Memberships
- Member
- Member
- Society for Immunotherapy of CancerMember
Hospital Affiliations
UW Medicine/Harborview Medical CenterSeattle, Washington
UW Medicine/University of Washington Medical CenterSeattle, Washington
Seattle VA Medical CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
